Artios Pharma Secures $115M to Advance Cancer Therapies
November 19, 2025, 9:32 am
Artios Pharma, a UK-based biotech firm, has secured $115 million in Series D funding. The financing aims to boost the development of its precision cancer treatments. Focus on DNA damage response (DDR) is key. Funds will advance clinical trials for alnodesertib and ART6043. These therapies target cancers with high unmet needs.
Artios Pharma, a UK-based biopharmaceutical company, has successfully closed a $115 million Series D financing round. The funding will fuel the advancement of its precision cancer treatment pipeline. The company focuses on therapies targeting the DNA damage response (DDR) in cancer cells.
Artios Pharma is pioneering next-generation approaches in the DDR field. They aim to develop drugs that exploit DDR pathways. Their goal is to improve outcomes for patients with hard-to-treat cancers.
The company's lead candidates include:
*Alnodesertib:
Artios Pharma Raises $115 Million to Accelerate Cancer Drug Development
Artios Pharma, a UK-based biopharmaceutical company, has successfully closed a $115 million Series D financing round. The funding will fuel the advancement of its precision cancer treatment pipeline. The company focuses on therapies targeting the DNA damage response (DDR) in cancer cells.
DDR-Targeted Therapies Show Promise
Artios Pharma is pioneering next-generation approaches in the DDR field. They aim to develop drugs that exploit DDR pathways. Their goal is to improve outcomes for patients with hard-to-treat cancers.
The company's lead candidates include:
*
Alnodesertib: An ATR inhibitor currently in clinical trials.
* ART6043: A DNA Polymerase theta (Polθ) inhibitor also in clinical trials.
These drugs, along with pre-clinical programs like DDRi-ADCs, are designed to precisely eliminate cancer cells. They target the remaining survival mechanisms.
Funding to Expand Clinical Trials
The Series D proceeds will expand the clinical evaluation of alnodesertib. The trials will enroll more ATM-negative patients. These patients will have second-line pancreatic cancer and third-line colorectal cancer. The FDA recently granted Fast Track Designation for this program.
The financing will also initiate a Phase 2 randomized clinical trial for ART6043. This trial will focus on patients with BRCA-mutant HER2-negative breast cancer. These patients must be eligible for PARP inhibitor treatment.
Alnodesertib Demonstrates Durable Responses
There are currently no approved therapies for tumors with ATM-deficiency. Alnodesertib has shown durable responses in these patients across various solid tumors. Data from the STELLA Phase 1/2a trial showed a 50% confirmed overall response rate. This was seen in patients with ATM-negative solid tumors treated with alnodesertib and low-dose irinotecan.
ART6043 Shows Promising Clinical Signals
ART6043, the Polθ inhibitor, has demonstrated an attractive tolerability profile. Early clinical data suggests promising activity.
Investors Back Artios' Vision
The Series D round was co-led by SV Health Investors and RA Capital Management. New investors like Janus Henderson Investors also participated. Existing investors showed broad support.
Other investors included:
* Andera Partners
* Avidity Partners
* EQT Life Sciences
* Invus
* IP Group plc
* M Ventures
* Novartis Venture Fund
* Omega Funds
* Pfizer Ventures
* Piper Heartland
* Sofinnova Partners
* Schroders Capital
CEO Highlights Accelerated Development
Artios CEO Mike Andriole stated that the Series D accelerates the path to registration for both alnodesertib and ART6043. He emphasized the focus on cancers with the highest unmet needs. These include pancreatic, colorectal, and breast cancers.
SV Health Investors Pleased with Progress
Nikola Trbovic, Managing Partner at SV Health Investors, expressed excitement about Artios' evolution. He highlighted the company's promising and differentiated pipeline.
RA Capital Management Co-Leads Financing
Jake Simson, Partner at RA Capital Management, emphasized the potential of Artios' DDR-targeted therapies. He noted the observed responses and early clinical results.
European Biotech Sector Sees Strong Funding
In 2025, several European oncology-focused startups secured significant funding. This includes Tubulis (€308 million), Adcytherix (€105 million), T-Therapeutics (€78.2 million), CHARM Therapeutics (€68.5 million), NUCLIDIUM (€84 million), and Exeliom Biosciences (€2.85 million). These financings represent a substantial investment in European oncology and related fields.
Artios Pharma's $115 million raise positions it among the top-funded companies in this sector.
"
*
ART6043: A DNA Polymerase theta (Polθ) inhibitor also in clinical trials.
These drugs, along with pre-clinical programs like DDRi-ADCs, are designed to precisely eliminate cancer cells. They target the remaining survival mechanisms.
Funding to Expand Clinical Trials
The Series D proceeds will expand the clinical evaluation of alnodesertib. The trials will enroll more ATM-negative patients. These patients will have second-line pancreatic cancer and third-line colorectal cancer. The FDA recently granted Fast Track Designation for this program.
The financing will also initiate a Phase 2 randomized clinical trial for ART6043. This trial will focus on patients with BRCA-mutant HER2-negative breast cancer. These patients must be eligible for PARP inhibitor treatment.
Alnodesertib Demonstrates Durable Responses
There are currently no approved therapies for tumors with ATM-deficiency. Alnodesertib has shown durable responses in these patients across various solid tumors. Data from the STELLA Phase 1/2a trial showed a 50% confirmed overall response rate. This was seen in patients with ATM-negative solid tumors treated with alnodesertib and low-dose irinotecan.
ART6043 Shows Promising Clinical Signals
ART6043, the Polθ inhibitor, has demonstrated an attractive tolerability profile. Early clinical data suggests promising activity.
Investors Back Artios' Vision
The Series D round was co-led by SV Health Investors and RA Capital Management. New investors like Janus Henderson Investors also participated. Existing investors showed broad support.
Other investors included:
* Andera Partners
* Avidity Partners
* EQT Life Sciences
* Invus
* IP Group plc
* M Ventures
* Novartis Venture Fund
* Omega Funds
* Pfizer Ventures
* Piper Heartland
* Sofinnova Partners
* Schroders Capital
CEO Highlights Accelerated Development
Artios CEO Mike Andriole stated that the Series D accelerates the path to registration for both alnodesertib and ART6043. He emphasized the focus on cancers with the highest unmet needs. These include pancreatic, colorectal, and breast cancers.
SV Health Investors Pleased with Progress
Nikola Trbovic, Managing Partner at SV Health Investors, expressed excitement about Artios' evolution. He highlighted the company's promising and differentiated pipeline.
RA Capital Management Co-Leads Financing
Jake Simson, Partner at RA Capital Management, emphasized the potential of Artios' DDR-targeted therapies. He noted the observed responses and early clinical results.
European Biotech Sector Sees Strong Funding
In 2025, several European oncology-focused startups secured significant funding. This includes Tubulis (€308 million), Adcytherix (€105 million), T-Therapeutics (€78.2 million), CHARM Therapeutics (€68.5 million), NUCLIDIUM (€84 million), and Exeliom Biosciences (€2.85 million). These financings represent a substantial investment in European oncology and related fields.
Artios Pharma's $115 million raise positions it among the top-funded companies in this sector.
"
These drugs, along with pre-clinical programs like DDRi-ADCs, are designed to precisely eliminate cancer cells. They target the remaining survival mechanisms.
Funding to Expand Clinical Trials
The Series D proceeds will expand the clinical evaluation of alnodesertib. The trials will enroll more ATM-negative patients. These patients will have second-line pancreatic cancer and third-line colorectal cancer. The FDA recently granted Fast Track Designation for this program.
The financing will also initiate a Phase 2 randomized clinical trial for ART6043. This trial will focus on patients with BRCA-mutant HER2-negative breast cancer. These patients must be eligible for PARP inhibitor treatment.
Alnodesertib Demonstrates Durable Responses
There are currently no approved therapies for tumors with ATM-deficiency. Alnodesertib has shown durable responses in these patients across various solid tumors. Data from the STELLA Phase 1/2a trial showed a 50% confirmed overall response rate. This was seen in patients with ATM-negative solid tumors treated with alnodesertib and low-dose irinotecan.
ART6043 Shows Promising Clinical Signals
ART6043, the Polθ inhibitor, has demonstrated an attractive tolerability profile. Early clinical data suggests promising activity.
Investors Back Artios' Vision
The Series D round was co-led by SV Health Investors and RA Capital Management. New investors like Janus Henderson Investors also participated. Existing investors showed broad support.
Other investors included:
* Andera Partners
* Avidity Partners
* EQT Life Sciences
* Invus
* IP Group plc
* M Ventures
* Novartis Venture Fund
* Omega Funds
* Pfizer Ventures
* Piper Heartland
* Sofinnova Partners
* Schroders Capital
CEO Highlights Accelerated Development
Artios CEO Mike Andriole stated that the Series D accelerates the path to registration for both alnodesertib and ART6043. He emphasized the focus on cancers with the highest unmet needs. These include pancreatic, colorectal, and breast cancers.
SV Health Investors Pleased with Progress
Nikola Trbovic, Managing Partner at SV Health Investors, expressed excitement about Artios' evolution. He highlighted the company's promising and differentiated pipeline.
RA Capital Management Co-Leads Financing
Jake Simson, Partner at RA Capital Management, emphasized the potential of Artios' DDR-targeted therapies. He noted the observed responses and early clinical results.
European Biotech Sector Sees Strong Funding
In 2025, several European oncology-focused startups secured significant funding. This includes Tubulis (€308 million), Adcytherix (€105 million), T-Therapeutics (€78.2 million), CHARM Therapeutics (€68.5 million), NUCLIDIUM (€84 million), and Exeliom Biosciences (€2.85 million). These financings represent a substantial investment in European oncology and related fields.
Artios Pharma's $115 million raise positions it among the top-funded companies in this sector.
"